Tags

Type your tag names separated by a space and hit enter

Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications.

Abstract

Despite scientific efforts and significant progress in understanding the basic cellular event in pancreatic adenocarcinoma (PA), survival rates have not changed much during the last 20 years. Prognosis in pancreatic cancer remains unsatisfactory due to its late clinical presentation, low surgical resectability rates, and resistance to chemotherapy. Novel therapeutic strategies are needed in order to improve the prognosis of patients with PA. Improvement of our knowledge of the molecular biology of pancreatic cancer may have important clinical implications in pancreatic cancer risk assessment, early diagnosis, and management. In human pancreatic cancer, a specific sequence of oncogene and tumor suppressor gene alterations is observed, including K-ras, HER-2/neu, p16, p53, and DPC4. The prevalence of these genetic alterations rises with increasing severity of dysplasia of the ductal mucosal lesions. Drugs that target these molecular abnormalities hold great promise for PA treatment in the near future. The focus of this review is to evaluate the gene mutations in pancreatic cancer, with emphasis on those studies that are most important to the clinical practice. Our review also summarizes current aspects of PA treatment and the differential diagnosis of pancreatic cancer and chronic pancreatitis.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Digestive Tract Diseases, Medical University of Lódź, Poland. r-wojnarowska@wp.pl

    Source

    MeSH

    Adenocarcinoma
    ErbB Receptors
    Genes, Tumor Suppressor
    Genetic Therapy
    Humans
    Mutation
    Oncogenes
    Pancreatic Neoplasms

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't
    Review

    Language

    eng

    PubMed ID

    16940943

    Citation

    Talar-Wojnarowska, Renata, and Ewa Malecka-Panas. "Molecular Pathogenesis of Pancreatic Adenocarcinoma: Potential Clinical Implications." Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, vol. 12, no. 9, 2006, pp. RA186-93.
    Talar-Wojnarowska R, Malecka-Panas E. Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. Med Sci Monit. 2006;12(9):RA186-93.
    Talar-Wojnarowska, R., & Malecka-Panas, E. (2006). Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 12(9), pp. RA186-93.
    Talar-Wojnarowska R, Malecka-Panas E. Molecular Pathogenesis of Pancreatic Adenocarcinoma: Potential Clinical Implications. Med Sci Monit. 2006;12(9):RA186-93. PubMed PMID: 16940943.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. AU - Talar-Wojnarowska,Renata, AU - Malecka-Panas,Ewa, PY - 2004/08/31/received PY - 2005/12/01/accepted PY - 2006/8/31/pubmed PY - 2007/1/11/medline PY - 2006/8/31/entrez SP - RA186 EP - 93 JF - Medical science monitor : international medical journal of experimental and clinical research JO - Med. Sci. Monit. VL - 12 IS - 9 N2 - Despite scientific efforts and significant progress in understanding the basic cellular event in pancreatic adenocarcinoma (PA), survival rates have not changed much during the last 20 years. Prognosis in pancreatic cancer remains unsatisfactory due to its late clinical presentation, low surgical resectability rates, and resistance to chemotherapy. Novel therapeutic strategies are needed in order to improve the prognosis of patients with PA. Improvement of our knowledge of the molecular biology of pancreatic cancer may have important clinical implications in pancreatic cancer risk assessment, early diagnosis, and management. In human pancreatic cancer, a specific sequence of oncogene and tumor suppressor gene alterations is observed, including K-ras, HER-2/neu, p16, p53, and DPC4. The prevalence of these genetic alterations rises with increasing severity of dysplasia of the ductal mucosal lesions. Drugs that target these molecular abnormalities hold great promise for PA treatment in the near future. The focus of this review is to evaluate the gene mutations in pancreatic cancer, with emphasis on those studies that are most important to the clinical practice. Our review also summarizes current aspects of PA treatment and the differential diagnosis of pancreatic cancer and chronic pancreatitis. SN - 1234-1010 UR - https://www.unboundmedicine.com/medline/citation/16940943/Molecular_pathogenesis_of_pancreatic_adenocarcinoma:_potential_clinical_implications_ L2 - https://www.medscimonit.com/download/index/idArt/455275 DB - PRIME DP - Unbound Medicine ER -